Gilead Sciences GILD Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| AmBisome | $138M-0.7% | $118M+8.3% | $123M-5.4% | $129M-14.6% | $139M-3.5% | |
| Biktarvy | $3.36B+6.7% | $3.97B+5.1% | $3.69B+6.2% | $3.53B+9.2% | $3.15B+6.9% | |
| Descovy | $807M+37.7% | $819M+32.7% | $701M+19.6% | $653M+34.6% | $586M+37.6% | |
| Genvoya | $264M-27.5% | $380M-19.1% | $377M-16.0% | $377M-14.3% | $364M-9.7% | |
| Livdelzi | $133M+233% | —— | —— | —— | $40M— | |
| Odefsey | $221M-21.4% | $310M-7.7% | $277M-15.0% | $298M-5.4% | $281M-9.4% | |
| Other HIV | $73M-19.8% | $190M+69.6% | $112M+12.0% | $107M+1.9% | $91M-22.2% | |
| Other Liver Disease | $114M-5.8% | $281M+116% | $231M+99.1% | $201M+77.9% | $121M+13.1% | |
| Other | $58M-17.1% | $86M+14.7% | $61M-14.1% | $73M-43.8% | $70M-12.5% | |
| Royalty, contract and other revenues | $14M-74.1% | $22M-33.3% | $424M+1,313% | $27M-34.1% | $54M+38.5% | |
| Sofosbuvir/Velpatasvir | $283M-18.2% | $276M-16.4% | $309M-19.7% | $342M-28.2% | $346M-14.6% | |
| Symtuza - Revenue share | $138M+21.1% | $133M-7.6% | $124M-10.8% | $124M-26.2% | $114M-19.1% | |
| Tecartus | $75M-3.8% | $90M-8.2% | $83M-15.3% | $92M-14.0% | $78M-22.0% | |
| Trodelvy | $402M+37.2% | $384M+8.2% | $357M+7.5% | $364M+13.8% | $293M-5.2% | |
| Veklury | $144M-52.3% | $211M-37.6% | $277M-60.0% | $121M-43.5% | $302M-45.6% | |
| Vemlidy | $237M-6.0% | $287M+10.4% | $280M+20.7% | $252M+3.7% | $252M+12.0% | |
| Yescarta | $332M-14.0% | $368M-5.4% | $349M-9.8% | $393M-5.1% | $386M+1.6% | |
| Yeztugo | $166M— | —— | —— | —— | $0— | |
| Total revenues by Geography | ||||||
| Europe | $1.14B+5.5% | $1.24B+5.2% | $1.56B+33.2% | $1.19B+4.9% | $1.08B-6.5% | |
| Rest of World | $889M-2.8% | $813M-1.6% | $933M+0.4% | $842M-4.2% | $915M+2.3% | |
| U.S. | $4.93B+5.5% | $5.88B+5.6% | $5.28B-3.1% | $5.05B+2.2% | $4.67B+0.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Gilead Sciences break its business down?
- Gilead Sciences (GILD) reports total revenues by product across 18 parts — AmBisome, Biktarvy, Descovy, Genvoya and Livdelzi. Each is extracted from the segment footnotes and tracked over time.
- Where does Gilead Sciences's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Gilead Sciences's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
